PATENT CLAIM ANALYSIS

Application Number: 15994502
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-03
Patent Classification: ["514", "183000"]

Abstract:
The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

Claim (Index 25):
The composition of  claim 12  wherein the composition comprises bisantrene and is formulated for use in a program of toxicity management and the toxicity management is a method of toxicity management selected from the group consisting of:\n (a) the use of colchicine or an analog thereof; \n (b) the use of a uricosuric; \n (c) the use of uricase; \n (d) the non-oral use of nicotinamide; \n (e) the use of a sustained-release form of nicotinamide; \n (f) the use of an inhibitor of polyADP-ribose polymerase; \n (g) the use of caffeine; \n (h) the use of leucovorin rescue; \n (i) the use of sustained-release allopurinol; \n (j) the non-oral use of allopurinol; \n (k) the administration of bone marrow transplant stimulants, blood, platelet infusions, Neupogen, G-CSF; or GM-CSF; \n (l) pain management; \n (m) the administration of anti-inflammatories; \n (n) the administration of fluids; \n (o) the administration of corticosteroids; \n (p) the administration of insulin control medications; \n (q) the administration of antipyretics; \n (r) the administration of anti-nausea treatments; \n (s) the administration of anti-diarrhea treatments; \n (t) the administration of N-acetylcysteine; \n (u) the administration of antihistamines; \n (v) the administration of agents for reduction of gastric toxicity; \n (w) administration of steroids as pre-treatment to prevent anaphylaxis; \n (x) administration of sympathetomimetics as pre-treatment to prevent anaphylaxis; and \n (y) administration of an agent to control or prevent chemotherapy-induced thrombocytopenia.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 93.0
- Lexical Diversity: 1.31579
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15979041', '14907728', '14907729', '13817096', '14250958']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8173485928027381
- 35 USC 102 Novelty (BERT): 0.5302338181463822
- Combined Prediction Score: 0.7886371153371025
- Mean Citation Score: 276.52593
- Max Citation Score: 362.98706
- Similarity Product: 286.1407873893058

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test